Debate synthesis

Post-Debate Synthesis for the Editor

Issue 1: Denominator artifact in the "persistent vascular maturation" claim (Fig. 1G–H)

Manuscript evidence: Vascular density is calculated as vascular cell count / total synovial cell area. Post-treatment biopsies show significant increases in capillary ECs, arteriolar ECs, pericytes, and VSMCs relative to healthy controls.

Skeptic's case: Immunosuppression is stated in the Introduction to deplete infiltrating immune cells; if the denominator (total cells) shrinks, vascular proportions rise mechanically even with no true change in vascular biology. The manuscript never reports absolute vascular cell counts per unit area, so this cannot be ruled out. This is the paper's headline claim (treatment-resistant vasculature), so the concern is serious.

Advocate's rebuttal: A pure denominator-shrinkage artifact would inflate all vascular subtypes sharing the same denominator equally. The manuscript reports a selective pattern — capillary/arteriolar ECs, pericytes, and VSMCs increase, while venular ECs and lymphatic ECs (same denominator) do not change significantly. This differential pattern is inconsistent with a uniform mechanical artifact and is more consistent with genuine arterial-side maturation.

Status: Unresolved, but narrowed. The advocate's selectivity argument is a genuine partial answer supported by manuscript text, and no one in the debate contested that the selective pattern is real. However, the debate did not establish that a denominator artifact could not produce differential effects across subtypes (e.g., if depleted immune cells co-localize non-uniformly with different vascular beds), and the underlying fix — reporting absolute cell counts per unit area — was never supplied. The concern is weakened but not eliminated; it should be reported as a live methodological question, not resolved in the paper's favor.

Issue 2: Missing sample sizes (n) across in vitro, co-culture, and explant experiments

Manuscript evidence: Figures 3, 4, and 6 report p-values (e.g., 36–40% aSMA reduction, 50–54% PECAM1 reduction) without stating n, pairing structure (paired vs. unpaired), or raw data points in figure legends or Methods.

Skeptic's case: This affects the headline therapeutic numbers used in the abstract; without n, degrees of freedom and therefore the validity of the reported statistics cannot be assessed by a reader.

Advocate's concession: Explicitly conceded as "a real and fair reporting gap" — but argued to be a disclosure failure rather than evidence the effects are spurious, since the same qualitative direction of effect recurs across five methodologically independent approaches.

Status: Resolved as a reporting/reproducibility deficiency, not as a validity problem. Both sides agree this is fixable by disclosure (stating n, pairing, raw points) and does not by itself invalidate the qualitative direction of the findings. It remains an unaddressed reproducibility gap that a reader currently cannot verify.

Issue 3: Fibroblast-to-mural-cell "differentiation" claim vs. marker/activation evidence

Manuscript evidence: Marker upregulation (ACTA2, MYH11, RGS5, CNN1) in cultured fibroblasts after neurotrophin stimulation; modest contractility (16–21% for BDNF/NT3, no significant NGF effect, Fig. 4D–F); increased aSMA around vasculature in explants (Fig. 4K).

Skeptic's case (raised independently by three reports — contribution_context, reporting_reproducibility, scientific_validity — and treated in debate as one clustered issue, not three corroborations): All methods deployed (co-culture, RNAscope, IHC, organoid staining) measure marker co-expression or induction, never lineage or fate. The title's use of "differentiation" is a stronger causal claim than marker convergence supports; the alternative explanations (activation of pre-existing mural cells, recruitment, endothelial-to-mesenchymal transition) are not excluded.

Advocate's response: Concedes this is "a genuine limitation on the fibroblast-origin claim specifically" but argues the better-supported, narrower claim — that neurotrophin signaling regulates acquisition of mural markers/function and is druggable — stands independently of the origin question.

Status: Unresolved on the strong claim, conceded as a limitation by the advocate. Both sides agree lineage tracing or scRNA-seq trajectory data would settle it. The narrower marker-induction claim is not disputed; the causal "differentiation" language in the title/abstract is not fully supported and this was not contested by the advocate in the final round.

Issue 4: TRK inhibitor effects — reversal vs. toxicity (Fig. 6)

Manuscript evidence: Larotrectinib/entrectinib reduce aSMA (36–40%) and PECAM1+ density (50–54%) in 3-day RA explants. No viability or apoptosis marker (e.g., cleaved caspase-3, LDH) is reported for treated vs. control explants.

Skeptic's case: Reduced vascular density could reflect endothelial toxicity or cell death rather than true reversal of maturation; the advocate's characterization of this as a "concrete path toward clinical translation" overclaims relative to the ex vivo, short-window, no-viability-control evidence.

Advocate's response: Did not directly rebut the viability/toxicity gap in the final round; instead reiterated that the qualitative direction is corroborated across methods reaching the mechanism, without addressing whether the explant readout specifically distinguishes reversal from toxicity.

Status: Unresolved. The advocate conceded no counter-evidence on this specific point. This bears on how strongly the therapeutic-relevance claim can be stated; it is not fatal to the mechanistic finding but does constrain the strength of the translational framing.

Concerns raised in reports but not engaged in debate

• NOTCH3 as primary/sole initiator of NGF (contribution_context, scientific_validity): correlative spatial co-localization; alternative endothelial/stromal NGF sources not excluded. Not discussed by either debater.
• NGFR-TRKA potentiation via overexpression only, with low endogenous NTRK1/NGFR in tissue (contribution_context, scientific_validity): physiological relevance of the overexpression-based mechanism is unaddressed in debate.
• Uncited overlapping literature (Chalkidi et al. 2025 on NOTCH3/pericytes in colorectal cancer; Luo et al. 2025 on BDNF/pericyte homeostasis; Ly et al. 2014 on neurotrophins in giant cell arteritis) — contribution_context's positioning concerns were not raised or contested in debate.
• Multiple-comparisons correction absent across ~18 pairwise tests in Fig. 1G (data_analysis, reporting_reproducibility) — not engaged.
• Data deposition gaps (Xenium accession, Seurat parameters, bulk RNA-seq for NGF/NGFR signature) (reporting_reproducibility) — not engaged.
• CRISPR/NOTCH3 knockout efficiency not reported (data_analysis, reporting_reproducibility) — not engaged.
• Ethics/compliance: no concerns raised (score 5/5, uncontested, not a debate topic).

These are silences, not resolutions, and should be weighed independently by the editor.